Rezolute's Second Chance: FDA Offers Lifeline for Failed Rare Disease Trial

REDWOOD CITY, CA – March 27, 2026 – In a dramatic reversal of fortune that sent its stock soaring, Rezolute, Inc. has secured a critical lifeline from the U.S. Food and Drug Administration for its lead drug candidate, ersodetug, despite the treatment failing to meet its primary goal in a pivotal Phase 3 study last year. The decision offers a glimmer of hope not only for the company but also for families grappling with the rare and devastating genetic disorder, congenital hyperinsulinism (HI).

Following a crucial Type B meeting on March 17, the FDA encouraged the late-stage rare disease company to submit a comprehensive data package from its sunRIZE trial for an independent review. This unexpected opening comes after Rezolute's shares plummeted over 78% in December 2025 when it announced the study had not shown a statistically significant reduction in hypoglycemia events compared to a placebo. The market's reaction to this week's news was immediate and enthusiastic, with shares jumping as much as 43% during Tuesday's trading session, reflecting renewed investor optimism in a program once left for dead.

A Trial Derailed by Human Behavior?

The central issue debated in the FDA meeting was not a lack of drug activity, but rather the complex and confounding nature of measuring efficacy in a real-world setting. The sunRIZE trial's primary endpoint relied on self-monitored blood glucose (SMBG) readings, a standard but intermittent method where patients or caregivers prick a finger to test blood sugar. Rezolute reported that while ersodetug reduced hypoglycemia events by about 45% from baseline, the placebo group also saw a remarkable 40% improvement, erasing any statistical advantage.

Rezolute argued that this was the result of a "pronounced study effect." In a condition as dangerous as congenital HI, where low blood sugar can quickly lead to seizures and irreversible brain damage, caregivers are hyper-vigilant. The company believes that the very act of being in a trial, combined with the unblinded nature of daily glucose monitoring, led participants in the placebo arm to intensify their standard care—such as providing more frequent feedings—to prevent hypoglycemic events. This behavioral compensation, they contend, masked the true benefit of ersodetug.

As evidence, the company pointed to data from continuous glucose monitors (CGM), which provide a more objective, 24/7 picture of blood sugar levels. These devices showed consistent and clinically meaningful improvements in time spent in hypoglycemia for patients on ersodetug compared to placebo. Although this key secondary endpoint also narrowly missed nominal statistical significance at the pre-specified final timepoint, the trend was clear and supported by biomarker data showing the drug was hitting its target in the insulin signaling pathway.

The FDA appeared receptive to this argument. According to Rezolute, the agency "acknowledged the challenges posed by the potential impact of varied behavioral factors on clinical trials in this heterogeneous patient population, including the associated limitations of self-monitored blood glucose (SMBG) based metrics."

“We are extremely encouraged by the outcome of our meeting with FDA including the fact that, while acknowledging their feedback was preliminary, the agency did not dismiss sunRIZE outright on the basis of not meeting its primary endpoint,” said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. “FDA was engaged with the content we presented, asked astute questions necessary to fully understand the results, and expressed a desire to conduct a thorough review that would assist in decision making regarding advancement of the program.”

Hope for a High Unmet Need

The FDA's flexibility highlights the severe unmet need in congenital HI. The disorder causes the pancreas to produce excessive insulin, leading to dangerously low blood sugar. Current treatments are limited and often come with significant drawbacks. The first-line therapy, diazoxide, is ineffective for many patients. Other options include somatostatin analogues like octreotide, which require injections and can have side effects. For the most severe, diffuse forms of the disease, the only definitive treatment is a near-total pancreatectomy—a highly invasive surgery that trades HI for a lifetime of diabetes and digestive issues.

Ersodetug, a monoclonal antibody that works by reducing the insulin receptor's over-activation, is designed to be a universal treatment for all forms of HI. This mechanism could provide a vital new option for patients who have exhausted other medical therapies and face the prospect of life-altering surgery.

Patient advocates, who attended the FDA meeting, were buoyed by the collaborative tone. “Our community has long awaited new treatment options, and this open dialogue reflects important progress toward potentially safely bringing more effective and better-tolerated therapies,” said Julie Raskin, Chief Executive Officer of Congenital Hyperinsulinism International. Her comments underscore the desperation for innovation in a field where management is a constant, exhausting battle for families.

A Regulatory Gambit Backed by Precedent

While seeking approval after a failed primary endpoint is a high-stakes gamble, it is not without precedent, particularly in rare diseases where small patient populations and disease complexity make traditional trial designs challenging. Between 2018 and 2021, the FDA approved roughly 10% of new drugs that had missed a primary endpoint in at least one pivotal trial, often basing the decision on compelling secondary endpoint data, subgroup analyses, or a totality of evidence.

Recent approvals, such as Sarepta's gene therapy Elevidys for Duchenne muscular dystrophy, which was approved based on a biomarker despite failing its primary functional endpoint, show the agency's willingness to apply regulatory flexibility when a strong biological rationale and a high unmet need exist. Rezolute's case appears to fit this mold, with the company armed with strong CGM data and a clear argument for why its primary endpoint was flawed.

Investors are now betting that this argument will be persuasive. The company, which reported a cash runway into mid-2027, has the financial stability to see the review process through. The next step is for Rezolute to submit its full study reports and analysis datasets to the FDA. The agency will then conduct its own independent evaluation to determine if the evidence is sufficient to support a marketing application or if more information will be required.

Rezolute expects to provide an update on the program's path forward in the second half of 2026. In the meantime, the company is also advancing ersodetug in a separate Phase 3 study for tumor-induced hyperinsulinism, with results from that trial also expected later this year, providing another potential path to market for the promising antibody.